APLT - Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday November 7 | Benzinga
Forum to be Webcast Live
Topline Phase 3 Data Readout from ARISE-HF Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy On Track for 4Q 2023
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will host a Diabetic Cardiomyopathy (DbCM) expert forum with key opinion leaders on Tuesday, November 7, 2023 at 8:00 a.m. ET.
Members of the Company's senior management team will be joined by the following key opinion leaders:
- James Januzzi, MD, Hutter Family Professor of Medicine, Harvard Medical School; Director, ...